BioNTech SE (NASDAQ:BNTX) to Post Q3 2024 Earnings of $0.72 Per Share, HC Wainwright Forecasts

BioNTech SE (NASDAQ:BNTX) – Equities researchers at HC Wainwright lowered their Q3 2024 earnings per share (EPS) estimates for shares of BioNTech in a research note issued on Monday, October 7th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of $0.72 for the quarter, down from their previous forecast of $0.86. HC Wainwright currently has a “Buy” rating and a $150.00 target price on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($2.87) per share. HC Wainwright also issued estimates for BioNTech’s Q4 2024 earnings at $0.47 EPS, FY2024 earnings at ($3.92) EPS, Q1 2025 earnings at ($2.48) EPS, Q2 2025 earnings at ($2.55) EPS, Q3 2025 earnings at $0.59 EPS, Q4 2025 earnings at $0.54 EPS and FY2025 earnings at ($3.88) EPS.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The company had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. During the same quarter in the previous year, the firm posted ($0.86) earnings per share. BioNTech’s revenue for the quarter was down 23.3% on a year-over-year basis.

A number of other equities research analysts have also recently weighed in on BNTX. JPMorgan Chase & Co. upgraded BioNTech from an “underweight” rating to a “neutral” rating and upped their price target for the stock from $91.00 to $125.00 in a report on Monday, September 16th. Deutsche Bank Aktiengesellschaft raised their price target on BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, September 19th. Hsbc Global Res raised BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Morgan Stanley raised shares of BioNTech from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Finally, Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and upped their price target for the company from $96.00 to $150.00 in a report on Tuesday, September 17th. Five equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $131.92.

BioNTech Trading Up 0.8 %

Shares of BNTX opened at $118.37 on Wednesday. The firm’s 50-day moving average is $100.13 and its two-hundred day moving average is $93.16. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $28.14 billion, a P/E ratio of 236.74 and a beta of 0.24.

Institutional Trading of BioNTech

Several hedge funds and other institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC lifted its stake in shares of BioNTech by 121.0% during the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after purchasing an additional 150 shares during the period. Covestor Ltd increased its stake in BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in BioNTech by 106.3% during the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after buying an additional 252 shares during the period. Crewe Advisors LLC acquired a new stake in BioNTech in the 1st quarter worth about $75,000. Finally, American National Bank purchased a new stake in BioNTech in the 1st quarter valued at about $81,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.